Veeva Systems Inc.

Veeva Systems Inc. Earnings Recaps

VEEV Health Care 2 recaps
Next earnings: November 25, 2026 (estimated) · full calendar
Q2 2027 Aug 28, 2026

The stock rallied 14.3% post-earnings, driven by broad-based strength in the Commercial segment, particularly robust subscription growth, and strong initial momentum in AI initiatives including the new Veeva Falcon offering.

Key takeaways
  • Total revenue reached $928 million with non-GAAP operating income of $416 million, marking solid execution.
  • Commercial subscriptions increased approximately 13% year-over-year, with double-digit growth even excluding the Crossix acquisition.
  • Crossix continues to perform strongly alongside growth in core CRM offerings, dispelling concerns of market contraction.
  • Management highlighted high interest and early adoption potential in AI products like Veeva Falcon, which promises faster implementation and operational efficiencies.
  • Aspen, a new internal start-up focused on horizontal CRM with AI integration, remains in early stages with aggressive 90-day planning cycles.
Q4 2026 Mar 6, 2026

Veeva delivered robust financial results for Q4 and the full fiscal year 2026, exceeding revenue expectations and achieving a notable $3.195 billion in annual revenue, underscoring its position as a key player in the life sciences sector.

Key takeaways
  • Q4 total revenue reached $836 million, with non-GAAP operating income of $366 million.
  • Full-year revenue of $3.195 billion signifies successful growth, surpassing the $3 billion run rate goal.
  • Strategic partnerships in life sciences continue to strengthen, driven by demand for modernization and automation solutions.
  • While AI interest is growing among clients, the primary demand is for scalable core systems rather than AI-specific solutions.
  • CRM’s contribution to revenue is projected to decrease to about 10% by 2030, driven by a diverse business model and additional revenue from new product offerings.